HOME >> BIOLOGY >> NEWS
Pharmaceutical 'smart bomb' targets cancer cells

even in cancer cells is used as the activator. When researchers insert a gene for this enzyme into cancer cells, the cells start to express the nitroreductase, making them an easy target. The prodrug "bomb" goes off and unleashes the toxin that spreads to neighboring cells which ultimately kills the tumor.

The English contingent also developed a compound that is being evaluated in clinical trials as an anticancer prodrug. But Hu's new compounds appear to be even more potent. The overseas researchers are now testing the Rutgers compounds, side by side with their own, delivering them in the enhanced prodrug packages.

Initial testing on mammalian hamster cells shows that after 72 hours of drug exposure, the Rutgers compounds were as much as 100 times more effective in inhibiting cell growth. One-hour tests were also performed and, again, the Rutgers compounds were found to be superior as much as 30 times more effective than the English compound. Eighteen-hour tests on human ovarian cancer cells showed a still significant, tenfold superiority.

"Our cytotoxic compounds delivered to the cancer site in a revamped prodrug form clearly show great potential, but there are still lots of tests to be done," said Hu. "There are many preclinical studies ahead of us. If everything goes well, we could see clinical trials in humans in a couple of years."

Hu says that these compounds are not going to cure cancer by themselves. But they will be significant tools, most probably used in combination with other technologies one bullet of many in the arsenal of anticancer weapons.


'"/>

Contact: Joseph Blumberg
blumberg@ur.rutgers.edu
732-932-7084 Ext. 652
Rutgers, the State University of New Jersey
31-Dec-2000


Page: 1 2

Related biology news :

1. Warren Pharmaceuticals publishes results of preclinical evaluation
2. Cyclis Pharmaceuticals reports studies defining new mechanism for potential cancer therapies
3. Final results of the two Zevalin pivotal trials in radioimmunotherapy for B cell Non-Hodgkins Lymphoma announced by IDEC Pharmaceuticals
4. Pharmaceutical and personal care products: What happens when they enter the environment - an emerging concern
5. Researchers, Regulators, Industry, Consumer Advocates Gather to Discuss Critical Issues Facing the Pharmaceutical Industry
6. Ribozyme Pharmaceuticals, Inc. Demonstrates Potent Activity Of A Ribozyme Targeted Against The Hepatitis C Virus
7. Idun Pharmaceuticals Identifies Cell Type And Molecular Pathway Involved In TransplantationRelated Liver Damage
8. Cubist Pharmaceuticals Describes New VITA™ Technology For Enabling Genomics For Drug Discovery
9. Vertex Pharmaceuticals/Yale Research Team Uses Gene Knockout Mice To Establish Role Of Caspase-9 In Neuronal Cell Death Pathway
10. Micro-Plants Yield Pharmaceutical New Wave
11. Scientists At The Scripps Research Institute And R.W. Johnson Pharmaceuticals Develop New Antibacterial Agents

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/17/2018)... ... August 16, 2018 , ... With increasing safety requirements, and ... research projects, are presenting multiple challenges. To be successful in such a competitive environment, ... different aspects of the multiple tasks needed to develop a new drug or to ...
(Date:8/14/2018)... ... 2018 , ... Career fairs provide an ideal setting for ... at once. However, healthcare professionals often have hectic schedules with little spare time ... providers who wish to explore opportunities and learn about multiple employers from the ...
(Date:8/14/2018)... ... August 14, 2018 , ... ... and commercialization, is announcing the keynote for their NAVIGATE2018 conference. , ... as keynote speaker for NAVIGATE2018 , Cognition’s annual user conference. An experienced ...
Breaking Biology News(10 mins):
(Date:7/25/2018)... ... July 25, 2018 , ... ... its state-of-the-art Digital Vivarium™ and Vium Cloud approach to accelerate preclinical drug discovery ... Officer. Additionally, the company announced the appointment of Jeff Caron to the newly ...
(Date:7/25/2018)... ... 2018 , ... John McDonald, CEO of ClearObject , ... India Business Council (IIBC), an advocacy group to strengthen economic ties between Indiana ... McDonald joins an impressive roster of local and national business leaders from organizations ...
(Date:7/24/2018)... Texas (PRWEB) , ... July 24, 2018 , ... Boval ... to support blood bank reagent suppliers. In Boval’s early days most of the ... were added to produce BSA for diagnostic purposes after gel cards changed that market ...
(Date:7/22/2018)... ... 19, 2018 , ... Mitotech S.A, a Luxembourg based clinical ... 3 clinical program in Dry Eye Disease. Under the agreement Essex Bio-Investment will ... towards the first Phase 3 study starting as early as Fall 2018. ...
Breaking Biology Technology:
Cached News: